$360m Deal-making CEO of Oxford-based Prosidion to Address BioTrinity

Share Article

CEO of UK-based subsidiary of (OSI) Pharmaceuticals to present at a new biotechnology partnering conference which will showcase companies from the most successful biotech super-cluster in Europe, which has raised more in IPO, second round and private equity financing than any other region in recent years.

News Image
Under Anker Lundemose's leadership, our UK-based subsidiary, Prosidion, has established a portfolio of innovative drug candidates and demonstrated an ability to rapidly and effectively advance drug candidates to a clinical proof-of-concept.

Earlier this month, Colin Goddard, Ph.D., Chief Executive Officer of Prosidion's US-based parent company, OSI Pharmaceuticals, gave a very strong indication of his confidence in their UK subsidiary saying, "Under Anker Lundemose's leadership, our UK-based subsidiary, Prosidion, has established a portfolio of innovative drug candidates and demonstrated an ability to rapidly and effectively advance drug candidates to a clinical proof-of-concept."

Prosidion is one of more than 25 exciting biotech companies which are going to be showcased at BioTrinity 2007, the annual biotech partnering meeting organised by OBN (Oxfordshire Bioscience Network), the "MassBio" of the Southern UK region.

With just two months until BioTrinity 2007 - is your name still missing from the list of over 100 companies already participating in BioTrinity?

BioTrinity has seen a very early adoption of the larger players in the industry such as Merck, Pfizer, Genzyme, BMS, Eli Lilly and AstraZeneca. Considerable interest in BioTrinity's VC session has also been shown by companies such as SR-one, Novartis Venture Fund, 3i and Oxford Capital Partners. Exhibitor spaces were sold-out even before Christmas.

The preliminary programme has been published online and is constantly developing, with the confirmed participation of many exciting young companies such as PIraMed, ReNeuron, VASTox, Chroma Therapeutics, Surface Therapeutics and Glide Pharma. A very good level of international interest has also been generated by companies and government agencies from North America, Europe and Asia.

Dr Jon Rees, Director of Oxfordshire Bioscience Network said, "Prosidion's deal with Eli Lilly is a highly significant step in the growth and development of the South East biotech cluster, following hot on the heels of the acquisition of PowderMed by Pfizer late last year, together with record levels of fundraising of biotech companies in the region between 2004-6. What we are seeing in the recent financings of biotech companies by the market, and the levels of investment in Science Park Development around Oxfordshire with around 200,000sq ft under development, is a very clear sign of the bullish confidence in the prospects of our maturing drug discovery sector."

Companies confirmed as already participating in BioTrinity:

3i Group Plc

a2sp Limited

AF Engineering Services Ltd

Amplion

Argenta Discovery Ltd

AS-Tec Chemicals Ltd

AstraZeneca Pharmaceuticals

Bench International

Beta Technology

BioPark Hertfordshire

BioProcess UK

Biotechnology Finance Advisory Service

Boult Wade Tennant

Bristol-Myers Squibb

Business Link Kent

Charles Russell LLP

Chroma Therapeutics

CMS Cameron McKenna LLP

Cobra Biomanufacturing

Complete Legal

Constella Group Ltd

Cranmer Lawrence & Company

De Facto Communications

Diagnox

Dionex UK ltd.

Drug Discovery Today

EBD Group

Eli Lilly & Company Ltd

Epidyme Ltd

Ernst & Young LLP

Evolutec

Thermo Fisher Scientific

Focus Insurance

Genzyme Therapeutics Ltd

Glide Pharmaceuticals

GlycoForm Ltd

Guildhay Ltd

Health Protection Agency

IBI Biosolutions (India)

Incentec Ltd

Intellidos Consulting

Interea International

Invest in Denmark

iQur Ltd

James Cowper

Josfred International Limited

Kent Bioscience Network

Lab Support UK Ltd

London Biotechnology Network

Manches LLP

Marks & Clerk

MedNet Pharmacelsus

Merck Sharp Dohme

Microtest Matrices Ltd

Millipore

Miller Insurance Services (UK) Limited

M-Scan

National Physical Laboratories

Novartis Venture Fund

Novolytics Limited

On Assignment Lab Support UK

(OSI) Prosidion

Owen Mumford Ltd

Oxford BioMedica

Oxford Capital Partners

Oxford Expression Technologies

Oxford Science Park

Oxfordshire Bioscience Network

OXiGENE Inc.

Oxygen Healthcare Limited

Pall Life Sciences

PAREXEL Consulting

PerkinElmer

Pfizer

PharmaVentures Ltd

Phase7

Phynova

PIraMed Ltd

Prosonix Limited

Quintiles Ltd

Reed Scientific

ReNeuron Group plc

SAFC Pharma

South East Medical Devices Network (SEMDN)

S.R. One

School of Life Sciences, Oxford Brookes University

South East Health Technologies Alliance

Spirogen Ltd

Stimutran-SME

Surface Therapeutics

Surrey Enterprise Hub

Takeda Global R&D Centre

Tessella Support Services plc

Thames Valley Life Science Network (TVLSN)

TTP LabTech

Ubichem PLC

University of Brighton

University of Southampton

University of the West of England, Bristol

UK Trade and Investment

VASTox Ltd

Vivacta Ltd

VWR Biosciences

###

Share article on social media or email:

View article via:

Pdf Print